Bearish Options Activity in Snyder's-Lance (LNCE) Targeting Downside Below $30/Share -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
SunTrust Robinson Humphrey Downgrades Lance, Inc. (LNCE) to Hold
April 17, 2017 10:58 AM EDTSunTrust Robinson Humphrey downgraded Lance, Inc. (NASDAQ: LNCE) from Buy to Hold with a price target of $30.00.
The analyst believes the company's underlying issues such as higher promo levels and lower manufacturing will persist indefinitely. The analyst sees limited catalysts.
For... More
Pre-Open Movers 04/17: (CBLI) (ALR) (STRP) Higher; (OMED) (LNCE) (INCY) Lower (more...)
April 17, 2017 9:32 AM EDTToday's Pre-Open Stock Movers
Cleveland BioLabs, Inc. (NASDAQ: CBLI) 38.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has completed its review of a side-by-side analytical comparison of two formulations of entolimod. The FDA agreed with CBLI that these data indicate the in vitro analytical comparability of the formulations. Based on the outcome of its review, the FDA has provided CBLI with its consent for initiation of an in vivo biocomparability study of these formulations in non-human primates (NHP).
HTG Molecular Diagnostics, Inc. (Nasdaq:... More
Snyder's-Lance Inc. (LNCE) Warns for Q1, Confirm CEO Transition Plan
April 17, 2017 6:07 AM EDT(Updated - April 17, 2017 6:11 AM EDT)
Snyders-Lance, Inc. (NASDAQ: LNCE) today announced a CEO transition and reported preliminary unaudited financial results for the first quarter ended April 1, 2017.
CEO Transition Underway
Snyders-Lance, Inc. has announced that its President and CEO, Carl E. Lee, Jr., has retired after 12 years of service to the Company. Brian J. Driscoll, former President and CEO of Diamond Foods and a current Director of Snyders-Lance, has agreed to step in as interim CEO.
In announcing the transition, Chairman of the Board, James Johnston said the... More
